UNAUDITED GROUP RESULTS FOR THE PERIOD ENDED 31 MARCH 2019, CASH DIVIDEND DECLARATION AND TRADING STATEMENT

Highlights


Revenue 
+9.5%
to R12.4 billion

Normalised EBITDA
+2.2%
to R2.7 billion
Interim dividend of 40 cents per share
+5.3%

Investments for future growth
R74 million
(including opex and capex)
Normalised earnings per share
-9.4%
to 49.1 cents

Downloads

PDF DOWNLOADS

EXCEL DOWNLOADS

VIEW WEBCAST

Financials

Commentary

OVERVIEW

Despite a challenging healthcare trading environment, our focus on operational excellence has delivered a healthy overall performance. The Group experienced a positive six months for the period ended 31 March 2019, with Group revenue growing by 9.5% while normalised Group EBITDA increased by 2.2%.